The initiation of coverage by Leerink Partners with an Outperform rating and a price target significantly higher than the current trading price suggests a positive outlook for Regulus Therapeutics. This endorsement by a reputable analyst could lead to increased investor interest and potentially drive the stock price up in the short term.